Page 1

2 Abbott TOTAL COMPANY $ 10.9B SALES WORLDWIDE $ 1.40 ADJUSTED DILUTED EPS² + 22 % ON AN ORGANIC BASIS * KEY BUSINESS UNITS ON AN ORGANIC BASIS * REFLECTS 43 % RAISED FULL - YEAR 2021 EPS GUIDANCE GROWTH VERSUS PRIOR YEAR REFLECTS $ 5.00 to $ 5.10 38 % IN ADJUSTED DILUTED EPS4 + 8.9 % NUTRITION + 46.8 % + 13.1 % DIAGNOSTICS MEDICAL DEVICES GROWTH VERSUS PRIOR YEAR D + 15.3 % ESTABLISHED PHARMACEUTICALS THIRD - QUARTER 2021 RESULTS BUSINESS HIGHLIGHTS BASE BUSINESS STRENGTH ON AN ORGANIC BASIS * ► 12 % 16 % 13 % growth in Diagnostics year over year , excluding COVID - 19 testing Abbott sales growth , excluding COVID - 19 testing compared to 2019 growth in Medical Devices compared to 2019 , with double - digit growth in Electrophysiology Heart Failure , Structural Heart and Diabetes Care ADVANCES IN HEART DEVICES ▸ FDA approval for Amplatzer® Amulet® Left Atrial Appendage Occluder and Portico® with Flex Nav® transcatheter aortic valve replacement ( TAVR ) system ▸ Announced new data to support an expanded indication for CardioMEMS® HF System FREESTYLE LIBRE LEADERSHIP ► 39 % growth on an organic basis 10 FDA clearance for FreeStyle Libre® 2t . iOS app for use with compatible iPhones " World's leading¹2 continuous glucose monitoring system provides nearly 3.5 million users with breakthrough technology that is accessible and affordable CardioMEMS 302PM MyClu GLUCOSE IN SANGE Freestyle 112 * Organic sales growth exclude impact of foreign exchange . For full financial data and reconciliation of non - GAAP mamures , plane see our press release dated Oct. 20 , 2021 , available at www.abbattinvestor.com . 1. Ona GAAP basis , third - quarter Abbott sales increased 23 % . 2. Third - quarter GAAP diluted EPS was $ 1.17.3 . Third - quarter diluted EPS from GAAP bois reflects 70 % growth 4 to er GAAP of $ 3.55 to $ 3.65 . Abbott forecants 2021 n , restructuring and en in induding exo kon its C 2021 diluted eamings per share fe intangible amortization consnung operations und related busines with changes during the year in current and projected testing demand , expenses asociated with acquisitions and other ret expanzm . Excluding spezifeditams , projected adjusted diluted earnings par share from continuing operations would be $ 5.00 to $ 5.10 for full - year 2021 5. Full - year 2021 guidance for diluted EPS from continuing operations on a GAAP basis reflects growth of 45 % at the mid - point venus the prior year . 6. On a GAAP basis , Diagnostica sales increased 48.2 % ; Medical Devices sales increased 14.6 % ; Nutrition sales incremed 9.6 % ; Established Pharmaceuticals sale increased 15.1 % 7. On a GAAP bais , third - quarter Abbott sales , excluding COVID - 19testing - related sales , increased 12 % compared to sales in 2019. & On a GAAP basis , third - quarter sales for Medical Devices incremed 19 % compared to sale in 2019. 9. On a GAAP bain , third - quarter sales , for Diagnostics , excluding COVID - 19 tenting - related sales , increased 14 % 10. Ona GAAP basis , FreeStyle Libre and Libre Sanse increased 42 % 11 The Freestyle Libre 2 app is only compatible with certain mobile devices and operating systems . Please check our website for more information about device compatibility before using the app . Use of the FreeStyle Libre 2 app require registration with LibraView 12. Data on file , Abbott Diabetes Care . Data based on the number of users worldwide for the Free Style Libre system compared to the number of users for other leading personal use , sensor - based glucose monitoring systems . + Find important safety information about the Free Style Libre portfdic www.freestylelibre.cn/safety-information . FORWARD - LOOKING STATEMENTS Some statements in this neva relame may be forward - looking statements for purposes of the Private Securition Litigation Reform Act of 1995. Abbott cautions that these forward - looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward - looking statements Economic , competitive , govemmental , technological and other factors that may affect Abbott's operations are discussed in Item 1A , " Risk Factors " in our Annual Report on Form 10 - K for the year anded Dec. 31 , 2020 , and are incorporated herein by reference . Abbott undertalom no obligation to relame publidy any revisions to forward - looking statements as a result of subsequent events or developments , except as required by law . 7